scholarly journals Aspirin Desensitization: Implications for Acetylsalicylic Acid-Sensitive Pregnant Women

Medicina ◽  
2021 ◽  
Vol 57 (4) ◽  
pp. 390
Author(s):  
Filipe Benito-Garcia ◽  
Inês Pires ◽  
Jorge Lima

Low-dose acetylsalicylic acid (ASA) is widely used during pregnancy to prevent obstetric complications of placental dysfunction, such as preeclampsia, stillbirth and fetal growth restriction, and obstetric complications in pregnant women with antiphospholipid syndrome. ASA-sensitive pregnant women cannot benefit from the effects of ASA due to the possibility of severe or potentially life-threatening hypersensitivity reactions to ASA. ASA desensitization is a valuable and safe therapeutic option for these women, allowing them to start daily prophylaxis with ASA and prevent pregnancy complications. The authors discuss the recent advances in obstetric conditions preventable by ASA and the management of ASA hypersensitivity in pregnancy, including ASA desensitization. To encourage the implementation of ASA desensitization protocols in ASA-sensitive pregnant women, they also propose a practical approach for use in daily clinical practice.

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 5976-5976
Author(s):  
Aleksei Bazhenov ◽  
Gennadii M. Galstian ◽  
Vera V. Troitskaya ◽  
Elena N. Parovichnikova ◽  
Sergei Makhinya ◽  
...  

Abstract Background: Acute leukemia (AL) during pregnancy is a rare event. The incidence of AL in pregnancy has been reported as one in 100 000 [1]. The serious complications may be caused in these women as by pregnancy as by AL and chemotherapy. Aim: To evaluate the outcomes of pregnant women with AL admitted in ICU due to life-threatening complications before delivery. Patients (Pts) and Methods: 20 pregnant women with AL admitted in the intensive care unit (ICU) due to the life-threatening complications were included in retrospective study (1996-2016). The reasons for ICU admission, chemotherapy, delivery features and outcomes of mothers and children were assessed. Results: 14 pts had acute myeloid leukemia (AML), 2 two of them with acute promyelocytic leukemia, 6 pts had acute lymphoblastic leukemia (ALL), age 18-40 yrs., median 30 yrs. Gestation age on ICU admission was 14-36 week, median 32 week. In 19 women AL was manifested during pregnancy, one woman had relapse of AL. 15 pts received induction chemotherapy before ICU admission (7+3, AIDA ALL-2009). 12 pts were severe neutropenic (WBC <0.5*109/l). The reasons for ICU admission were hypoxemic acute respiratory failure (ARF) (13 pts), acute renal failure (4 pts), sepsis (6 pts). ARF developed as result of pneumonia (10), pulmonary edema (2), ATRA syndrome (1). Lung ultrasound was used in pts with ARF to avoid radiation exposure. Bronchoalveolar lavage was done in 6 pts. The most common pathogen causing pneumonia was Pneumocystis jirovecii (4 pts), all of them were treated with trimethoprim/sulfamethoxazole. One woman had cytomegalovirus infection. 2 pts were noninvasive ventilated and 2 patients were mechanically ventilated. 4 pts received noradrenaline. Hemodialysis was required in 1 pregnant woman. All women had anemia (Hb levels from 65 to 114 g/l, median 85 g/l) and thrombocytopenia (from 10*109/l to 140*109/l, median 65*109/l). 1 woman with pneumocystic pneumonia had miscarriage and died 3 days after due to ARF. One woman died due to ARF on the 18-20 weeks of gestation age. Fast improvement was achieved in 3 women and they were discharged from ICU before delivery. Remained 15 women required urgent cesarean section and they delivered in ICU. In total, only 1 woman had vaginal birth, 17 pts required cesarean section. Cesarean sections were performed under general anesthesia in 13 pts and spinal anesthesia in 3 pts. Blood loss was from 200 to 1500 ml, median 803 ml. 16 children were born alive (APGAR scores 6-8), 1 child died 11 days after delivery due to ARF, 1 child was born with Down's syndrome and heart malformation. After delivery all women were discharged from ICU. In all pts the chemotherapy of AL was continued after delivery. The median overall survival of pts with acute leukemia who required ICU admission during pregnancy was 13.9 months. Conclusion: In the most pregnant pts life-threatening complication were associated with neutropenia. The frequent complication was ARF due to pneumonia, especially caused Pneumocystis jirovecii. Despite life-threatening complications, potentially adverse effect on the fetus of antibiotic therapy and chemotherapy the majority of pregnant women delivered the healthy children. Reference. 1.Hurley TJ, McKinnell JV, Irani MS. Hematologic malignancies in pregnancy. Obstet Gynecol Clin North Am. 2005; 32: 595-614. Disclosures No relevant conflicts of interest to declare.


2016 ◽  
Vol 24 (4) ◽  
pp. 96-103
Author(s):  
M Ayari ◽  
V G Demikhov ◽  
I M Mirov ◽  
E N Zinovyeva ◽  
O N Zhourina ◽  
...  

Currently, there is evidence that hepcidin is the main regulator of iron metabolism in human and pathogenesis key factor for anemia of inflammation. However, the role of hepcidin in multifactorial pathogenesis of anemia in pregnancy is not clear. We presented the results of the laboratory examinations of 78 pregnant women sera in hepcidin, ferritin, erythropoietin during pregnancy, and 116 sera of pregnant women with iron deficiency anemia (IDA) and anemia of mixed origin. The obtained data indicate a statistically significant decrease in the mean hepcidin concentration in pregnants versus non pregnant women. Mean hepcidin level in pregnant women with IDA was decreased, compared with anemia of mixed origin pregnants (p<0.0001). Evaluation of hepcidin concentrations may be useful laboratory test for differential diagnostic of anemia during pregnancy and for determination of optimal therapeutic option between oral iron, parenteral iron or using erythropoiesis -stimulating agents (ESAs) in combination with iron products.


2010 ◽  
Vol 3 (3) ◽  
pp. 90-93 ◽  
Author(s):  
Renee Bittoun ◽  
Giuseppe Femia

Managing smoking cessation during pregnancy is vital to the wellbeing of the fetus and the mother. Women who continue to smoke during pregnancy expose the fetus to thousands of chemicals which have been shown to cause deleterious short- and long-term effects. Although a large majority of women cease smoking early in the pregnancy, many of them relapse following delivery. Following a review of current research, an overview of the safety and efficacy of smoking cessation treatments for pregnant women will be considered. Limited research has been performed in this field; however, it can be concluded that low-dose intermittent nicotine replacement therapy is a safe treatment modality for women who smoke during pregnancy. At present there has been no research on other current smoking cessation treatments; however, we will suggest techniques to improve cessation rates and strategies to reduce relapse.


1992 ◽  
Vol 4 (2) ◽  
pp. 37-57 ◽  
Author(s):  
Henk A Bremer ◽  
Henk CS Wallenburg

Aspirin, acetylsalicylic acid, is the most frequently consumed drug in pregnancy, taken mostly without a prescription because of headache or a minor ailment. Numerous preparations containing acetylsalicylic acid are freely available over the counter under a variety of proprietary names, and in many cases pregnant women and their doctors may be unaware that aspirin is being taken.


Curationis ◽  
2006 ◽  
Vol 29 (3) ◽  
Author(s):  
LC Kumbani ◽  
P Mclnerney

Pregnant women in Malawi receive information about pregnancy, labour and delivery during routine antenatal visits. This study aimed to explore knowledge of obstetric complications amongst primigravidae attending an urban health centre in Blantyre, Malawi. A descriptive study design was used. Recognition of obstetric complications in pregnancy, during labour and after delivery and actions that participants would take if they developed any complications in pregnancy and after delivery were explored. Actions that women would take for complications that occur during labour were not probed, as women have little control over actions taken when complications arise during labour. Methods: Participants were selected by means of purposive sampling from a population of pregnant women who fitted defined criteria and who were attending antenatal clinic at a health centre. Forty-five primigravidae from the urban setting with a gestation period between 28 and 42 weeks were interviewed. Data were analysed manually. Results: The findings showed that participants were more aware of obstetric complications that could occur in pregnancy than of complications that may occur during and after delivery. Sixty percent of the participants were knowledgeable about obstetric complications in pregnancy. The majority of the participants, 73% and 82.2% did not know of any problems that could occur during and after the birth of the baby respectively. Participants had limited knowledge of complications that may need immediate treatment during all three periods. Fifty-eight percent (95% ci: 43; 73) of the primigravidae had some knowledge and could make an informed decision to go to a health facility with pregnancy complications. However, only 24% (95% ci: 11; 38) of the primigravidae had some knowledge and could make an informed decision to go to a health facility with complications after delivery. These findings suggest a critical need for provision of information on obstetric complications especially those that may occur during and after birth with emphasis on those obstetric complications that require immediate treatment.


Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Pratibha Dwarkanath ◽  
Alfa Muhihi ◽  
Christopher R. Sudfeld ◽  
Shobha Rani ◽  
Christopher P. Duggan ◽  
...  

Abstract Background Hypertensive disorders of pregnancy are important causes of maternal morbidity and mortality, as well as preterm birth, the leading cause of death for children under 5 years globally. The World Health Organization currently recommends that pregnant women receive high-dose calcium supplementation (1500–2000 mg elemental calcium) for prevention of preeclampsia in populations with low dietary calcium intake. Trials of low-dose calcium supplementation (< 1000 mg elemental calcium/day) during pregnancy have also shown similar reductions in the risk of preeclampsia; however, no trials to date have directly compared low-dose to the standard high-dose calcium supplementation. Our objective is to assess the non-inferiority of low-dose as compared to standard high-dose calcium supplementation in pregnancy. Methods/design We will conduct two independent trials in Bangalore, India (n = 11,000 pregnancies), and Dar es Salaam, Tanzania (n = 11,000 pregnancies). The trial designs are individually randomized, parallel group, quadruple-blind, non-inferiority trials of low-dose calcium supplementation (500 mg elemental calcium/day) as compared to standard high-dose calcium supplementation (1500 mg elemental calcium/day) among nulliparous pregnant women. Pregnant women will be enrolled in the trial before 20 weeks of gestation and will receive the randomized calcium regimen from randomization until the time of delivery. The co-primary outcomes are (i) preeclampsia and (ii) preterm birth; we will test non-inferiority of the primary outcomes for low-dose as compared to the standard high-dose supplementation regimen in each trial. The trials’ secondary outcomes include gestational hypertension, severe features of preeclampsia, pregnancy-related death, third trimester severe anemia, fetal death, stillbirth, low birthweight, small-for-gestational age birth, and infant death. Discussion The trials will provide causal evidence on the non-inferiority of low-dose as compared to the standard high-dose supplementation in India and Tanzania. A single tablet, low-dose calcium supplementation regimen may improve individual-level adherence, reduce programmatic costs, and ultimately expand implementation of routine calcium supplementation in pregnancy in populations with low dietary calcium intake. Trial registration ClinicalTrials.gov identifier: NCT03350516; registered on 22 November 2018. Clinical Trials Registry—India identifier: CTRI/2018/02/012119; registered on 23 February 2018. Tanzania Medicines and Medical Devices Authority Trials Registry identifier: TFDA0018/CTR/0010/5; registered on 20 December 2018.


Open Medicine ◽  
2010 ◽  
Vol 5 (3) ◽  
pp. 369-371
Author(s):  
Talay Kudaiberdiev ◽  
Gulzad Imanalieva ◽  
Gulbarchin Usupbaeva ◽  
Rahat Kalieva ◽  
Elmira Tukusheva

AbstractHypothyroidism in pregnancy is associated with serious maternal and fetal risk. Rarely, it is manifested by life-threatening cardiac complications, such as gross pericardial effusion and tamponade. We present a case of successfully treated gross pericardial effusion and tamponade in a 22-week pregnant woman with hypothyroidism. The patient was treated by pericardial drainage with further treatment of hypothyroidism with levothyroxine. During the follow-up pregnancy was uncomplicated without recurrence of pericardial effusion and successful delivery of full-term baby. We conclude that careful monitoring of thyroid functional tests and proper management should be performed in pregnant women with hypothyroidism to prevent cardiac complications of the disease, like pericardial effusion and tamponade.


2021 ◽  
Vol 15 (1) ◽  
pp. 22-31
Author(s):  
D. R. Eremeeva ◽  
M. S. Zainulina ◽  
Yu. S. Dolgova ◽  
R. A. Shakhaliev ◽  
O. A. Silvanovich ◽  
...  

Aim: to evaluate efficacy of plasmapheresis combined with low molecular weight heparins (LMWH) and acetylsalicylic acid (ASA).Materials and Methods. 327 plasmapheresis sessions were performed for 75 patients: 17 (22.6 %) patients during preparation for pregnancy, 11 (19.0 %) pregnant women in the first trimester, 33 (56.9 %) pregnant women in the second trimester, and 34 (58.6 %) pregnant women in the third trimester. Study inclusion criteria were as follows: high titers of antiphospholipid antibodies (APA) as well as included non-inclusion criteria in pregnant women with miscarriages and unfavorable anamnestic pregnancy outcome. 36 (62.1 %) women had pregnancy loss in anamnesis. All patients received low-dose ASA and LMWH therapy; 15 (25.86 %) pregnant women also received courses of intravenous immunoglobulins in the first and second trimesters.Results. 47 pregnant women had delivery, whereas 10 of women had pregnancy in progress. Term delivery was in 40 (85.1 %) patients, so that 23 (48.9 %) pregnant women had delivery per vias naturales. The average weight of the fetus was 3364.00 ± 393.76 g, height - 52.13 ± 1.82 cm. In 100 % cases, Apgar score was 8 points. 24 (51.1%) pregnant women had delivery via cesarean section. The average blood loss comprised 528.64 ± 166.10 ml. The average fetal weight in group after surgical delivery was 2982.14 ± 582.88 g, average height - 49.14 ± 4.09 cm, the Apgar score - 7.69 ± 0.47 points. Preterm births were observed in 7 (14.9%) cases, all via cesarean section. In 1 case, early fetal death was at gestational age of 8/9 weeks; according to the karyotyping data, a fetal chromosomal abnormality was detected. No severe obstetric complications were observed.Conclusions. Combining plasmapheresis with low dose LMWH and ASA therapy demonstrated high efficacy in treating obstetric APS manifested as high percentage of favorable pregnancy outcomes and low number of obstetric complications. 


Sign in / Sign up

Export Citation Format

Share Document